<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        94-334-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEFAXON 1GM I.V VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTRIAXONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        48.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Al Hikma Pharmaceutical Portugal Lda" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Al Hikma Pharmaceutical Portugal Lda
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cefaxon is an antibiotic given to adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.</p><p>&nbsp;</p><p><strong>Cefaxon is used to treat infections of:</strong></p><ul><li>The brain (meningitis).</li><li>The lungs.</li><li>The abdomen and abdominal wall (peritonitis).</li><li>The urinary tract and kidneys.</li><li>Bones and joints.</li><li>The skin or soft tissues.</li><li>The blood.</li><li>The heart.</li></ul><p><strong>It can be given: </strong></p><ul><li>To treat specific sexually transmitted infections (syphilis).</li><li>To treat patients with low white blood cell counts (neutropenia) who have fever due to bacterial infection.</li><li>To treat infections of the chest in adults with chronic bronchitis.</li><li>To treat Lyme disease (caused by tick bites) in adults and children including newborn babies from 15 days of age.</li><li>To prevent infections during surgery.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Cefaxon if:</strong></p><ul><li>You are allergic to ceftriaxone or any of the other ingredients of this medicine (listed in section 6).</li><li>You have had a sudden or severe allergic reaction to penicillin or similar antibiotics (such as cephalosporins, carbapenems or monobactams). The signs include sudden swelling of the throat or face which might make it difficult to breath or swallow, sudden swelling of the hands, feet and ankles, and a severe rash that develops quickly.</li></ul><p>&nbsp;</p><p><strong>Cefaxon must not be given to babies if: </strong></p><ul><li>The baby is premature.</li><li>The baby is newborn (up to 28 days of age) and has certain blood problems or jaundice (yellowing of the skin or the whites of the eyes) or is to be given a product that contains calcium into their vein.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before you are given Cefaxon if:</p><ul><li>You have recently received or are about to receive products that contain calcium.</li><li>You have recently had diarrhoea after having an antibiotic medicine. You have ever had problems with your gut, in particular colitis (inflammation of the bowel).</li><li>You have liver or kidney problems (see section 4).</li><li>You have gall stones or kidney stones.</li><li>You have other illnesses, such as haemolytic anaemia (a reduction in your red blood cells that may make your skin pale yellow and cause weakness or breathlessness).</li><li>You are on a low sodium diet.</li><li>You experience or have previously experienced a combination of any of the following symptoms: rash, red skin, blistering of the lips eyes and mouth, skin peeling, high fever, flu-like symptoms, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (signs of severe skin reactions, see also section 4 &ldquo;Possible side effects&rdquo;).</li></ul><p>&nbsp;</p><p><strong>If you need a blood or urine test </strong></p><p>If you are given Cefaxon for a long time, you may need to have regular blood tests. Cefaxon can affect the results of urine tests for sugar and a blood test known as the Coombs test. If you are having tests:</p><ul><li>Tell the person taking the sample that you have been given Cefaxon.</li></ul><p>&nbsp;</p><p>If you are diabetic or need to have your blood glucose level monitored you should not use certain blood glucose monitoring systems which may estimate blood glucose incorrectly while you are receiving ceftriaxone. If you use such systems check the instructions for use and tell your doctor, pharmacist or nurse. Alternative testing methods should be used if necessary.</p><p>&nbsp;</p><p><strong>Children </strong></p><p>Talk to your doctor or pharmacist or nurse before your child is administered Cefaxon if:</p><ul><li>He/she has recently been given or is to be given a product that contains calcium into their vein.</li></ul><p>&nbsp;</p><p><strong>Other medicines and Cefaxon</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>A type of antibiotic called an aminoglycoside.</li><li>An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes).</li></ul><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>The doctor will consider the benefit of treating you with Cefaxon against the risk to your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Cefaxon can cause dizziness. If you feel dizzy, do not drive or use any tools or machines. Talk to your doctor if you experience these symptoms.</p><p>&nbsp;</p><p><strong>Cefaxon contains sodium</strong></p><p>Cefaxon contains sodium. Each vial of Cefaxon 500 mg and 1000 mg Powder for Solution for Injection contains 41.492 mg or 82.984 mg sodium (main component of cooking/table salt); respectively. This is equivalent to 2.1% or 4.1%; respectively of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cefaxon is usually given by a doctor or nurse. It can be given as a drip (intravenous infusion) or as an injection directly into a vein.</p><p>&nbsp;</p><p>Cefaxon is made up by the doctor, pharmacist or nurse and will not be mixed with or given to you at the same time as calcium-containing injections.</p><p>&nbsp;</p><p><strong>The usual dose</strong></p><p>Your doctor will decide the correct dose of Cefaxon for you. The dose will depend on the severity and type of infection; whether you are on any other antibiotics; your weight and age; how well your kidneys and liver are working. The number of days or weeks that you are given Cefaxon depends on what sort of infection you have.</p><p>&nbsp;</p><p><em>Adults, older people and children aged 12 years and over with a body weight greater than or equal to 50 kilograms (kg):</em></p><ul><li>1000 to 2000 mg once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose (up to 4000 mg once a day). If your daily dose is higher than 2000 mg, you may receive it as a single dose once a day or as two separate doses.</li></ul><p>&nbsp;</p><p><em>Newborn babies, infants and children aged 15 days to 12 years with a body weight of less than 50 kg:</em></p><ul><li>50-80 mg Cefaxon for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose up to 100 mg for each kg of body weight to a maximum of 4000 mg once a day. If your daily dose is higher than 2000 mg, you may receive it as a single dose once a day or as two separate doses.</li><li>Children with a body weight of 50 kg or more should be given the usual adult dose.</li></ul><p>&nbsp;</p><p><em>Newborn babies (0-14 days)</em></p><ul><li>20-50 mg Cefaxon for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection.</li><li>The maximum daily dose is not to be more than 50 mg for each kg of the baby&rsquo;s weight.</li></ul><p>&nbsp;</p><p><em>People with liver and kidney problems</em></p><p>You may be given a different dose to the usual dose. Your doctor will decide how much Cefaxon you will need and will check you closely depending on the severity of the liver and kidney disease.</p><p>&nbsp;</p><p><strong>If you are given more Cefaxon than you should</strong></p><p>If you accidentally receive more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p>&nbsp;</p><p><strong>If you forget to use </strong><strong>Cefaxon</strong></p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not take a double dose (two injections at the same time) to make up for a missed dose.</p><p>&nbsp;</p><p><strong>If you stop using Cefaxon </strong></p><p>Do not stop taking Cefaxon unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p>Treatment with ceftriaxone, particularly in elderly patients with serious kidney or nervous system problems may rarely cause decreased consciousness, abnormal movements, agitation and convulsions.</p><p>&nbsp;</p><p><strong>Severe allergic reactions (not known, frequency cannot be estimated from the available data</strong><strong>)</strong></p><p>If you have a severe allergic reaction, tell a doctor straight away.</p><p>&nbsp;</p><p>The signs may include:</p><ul><li>Sudden swelling of the face, throat, lips or mouth. This can make it difficult to breathe or swallow.</li><li>Sudden swelling of the hands, feet and ankles.</li></ul><p>&nbsp;</p><p><strong>Severe skin reactions (not known, frequency cannot be estimated from the available data</strong><strong>)</strong></p><p>If you get a severe skin reaction, tell a doctor straight away.</p><p>&nbsp;</p><p>The signs may include:</p><ul><li>A severe rash that develops quickly, with blisters or peeling of the skin and possibly blisters in the mouth (Stevens-Johnson syndrome and toxic epidermal necrolysis which are also known as SJS and TEN).</li><li>A combination of any of the following symptoms: widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome).</li><li>Jarisch-Herxheimer reaction which causes fever, chills, headache, muscle pain, and skin rash that is usually self-limiting. This occurs shortly after starting ceftriaxone treatment for infections with spirochete such as Lyme disease.</li></ul><p>&nbsp;</p><p><strong><em>Other possible side effects:</em></strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Abnormalities with your white blood cells (such as a decrease of leucocytes and an increase of eosinophils) and platelets (decrease of thrombocytes).</li><li>Loose stools or diarrhoea.</li><li>Changes in the results of blood tests for liver functions.</li><li>Rash.</li></ul><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Fungal infections (for example, thrush or genital fungal infections).</li><li>A decrease in the number of white blood cells (granulocytopenia).</li><li>Reduction in number of red blood cells (anaemia).</li><li>Problems with the way your blood clots. The signs may include bruising easily and pain and swelling of your joints.</li><li>Headache.</li><li>Dizziness.</li><li>Feeling sick or being sick.</li><li>Pruritis (itching).</li><li>Pain or a burning feeling along the vein where ceftriaxone has been given. Blisters, deep redness or rash, burned areas, pain, irritation, itching at the injection site.</li><li>A high temperature (fever).</li><li>Abnormal kidney function test (blood creatinine increased).</li></ul><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>Inflammation of the large bowel (colon). The signs include diarrhoea, usually with blood and mucus, stomach pain and fever.</li><li>Difficulty in breathing (bronchospasm).</li><li>A lumpy rash (hives) that may cover a lot of your body, feeling itchy and swelling.</li><li>Blood or sugar in your urine.</li><li>Oedema (fluid build-up).</li><li>Shivering.</li></ul><p>&nbsp;</p><p><strong>Not known (Frequency cannot be estimated from the available data)</strong></p><ul><li>A secondary infection that may not respond to the antibiotic previously prescribed.</li><li>Form of anaemia where red blood cells are destroyed (haemolytic anaemia).</li><li>Severe decrease in white blood cells (agranulocytosis).</li><li>Convulsions.</li><li>Vertigo (spinning sensation).</li><li>Inflammation of the pancreas (pancreatitis). The signs include severe pain in the stomach which spreads to your back.</li><li>Inflammation of the mucus lining of the mouth (stomatitis).</li><li>Inflammation of the tongue (glossitis). The signs include swelling, redness and soreness of the tongue.</li><li>Problems with your gallbladder and/or liver which may cause pain, nausea, vomiting, yellowing of the skin, itching, unusually dark urine and clay coloured stools.</li><li>A neurological condition that may occur in neonates with severe jaundice (kernicterus).</li><li>Kidney problems caused by deposits of calcium ceftriaxone. There may be pain when passing water (urine) or low output of urine.</li><li>A false positive result in a Coombs&rsquo; test (a test for some blood problems).</li><li>A false positive result for galactosaemia (an abnormal build up of the sugar galactose).</li><li>Cefaxon may interfere with some types of blood glucose tests - please check with your doctor.</li></ul><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 25&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>Chemical and physical in-use stability of the reconstituted product and diluted solution has been demonstrated for at least 6 hours at or below 25&deg;C or 24 hours at 2-8&deg;C.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than the times stated above for the chemical and physical in-use stability.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ceftriaxone sodium.</p><p>&nbsp;</p><p>Each vial of Cefaxon 500 mg Powder for Solution for Injection contains 596.5 mg ceftriaxone sodium equivalent to 500 mg ceftriaxone.</p><p><strong>&nbsp;</strong></p><p>Each vial of Cefaxon 1000 mg Powder for Solution for Injection contains 1193 mg ceftriaxone sodium equivalent to 1000 mg ceftriaxone.</p><p>&nbsp;</p><p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cefaxon 500 mg Powder for Solution for Injection is an almost white or yellowish crystalline powder in colorless sealed vials with royal blue caps.

Cefaxon 1000 mg Powder for Solution for Injection is an almost white or yellowish crystalline powder in colorless sealed vials with white caps. 

After reconstitution, the color of solutions ranges from pale yellow to amber.

Pack size: 1 Vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2023; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سيفاكسون هو مضاد حيوي يعطى للبالغين والأطفال (بما في ذلك الأطفال حديثي الولادة) وهو يعمل عن طريق قتل البكتيريا التي تسبب الالتهابات. ينتمي إلى مجموعة من الأدوية تسمى السيفالوسبورينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يستخدم سيفاكسون لعلاج التهابات</strong><strong>:</strong></p><ul dir="rtl"><li>الدماغ (السحايا).</li><li>الرئتين.</li><li>جدار البطن والبطن (التهاب الصفاق).</li><li>المسالك البولية والكلى.</li><li>العظام والمفاصل.</li><li>الجلد أو الأنسجة الرخوة.</li><li>الدم.</li><li>القلب.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن أن يعطى:</strong></p><ul dir="rtl"><li>لعلاج التهابات محددة والتي تنتقل عن طريق الاتصال الجنسي (الزهري).</li><li>لعلاج المرضى الذين يعانون من انخفاض تعداد خلايا الدم البيضاء (العدلات) والذين يعانون من حمى بسبب عدوى بكتيرية.</li><li>لعلاج التهابات الصدر لدى البالغين الذين يعانون من التهاب الشعب الهوائية المزمن.</li><li>لعلاج مرض لايم (الناجم عن لدغات القراد) لدى البالغين والأطفال بما في ذلك الأطفال حديثي الولادة بعمر 15 يوم.</li><li>للوقاية من العدوى أثناء الجراحة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب إعطاؤك سيفاكسون</strong><strong> إذا</strong><strong>:</strong></p><ul dir="rtl"><li>كنت تعاني من حساسية من سيفترياكسون أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</li><li>حصل لديك رد فعل مفاجئ أو رد فعل حساسية شديد للبنسلين أو المضادات الحيوية المماثلة (مثل السيفالوسبورينات، أو الكاربابينيمات أو البيتا لاكتامات الأحادية). وتشمل العلامات تورم مفاجئ في الحلق أو الوجه والذي قد يجعل من التنفس أو البلع صعباً، تورم مفاجئ في اليدين والقدمين والكاحلين، والطفح الجلدي الشديد الذي يتطور بسرعة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب</strong><strong> ألا يعطى سيفاكسون للرضع إذا:</strong></p><ul dir="rtl"><li>كان الطفل خديج (ولد قبل موعده).</li><li>كان الطفل حديث الولادة (بعمر أقل من أو يساوي 28 يوم) ويعاني من مشاكل معينة في الدم أو اليرقان (اصفرار الجلد أو اصفرار بياض العينين) أو سيعطى المنتجات التي تحتوي على الكالسيوم في الوريد.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل أن يتم إعطاؤك سيفاكسون. في الحالات التالية إذا:</p><ul dir="rtl"><li>كنت قد تلقيت مؤخراً أو أنت على وشك أن تتلقى المنتجات التي تحتوي على الكالسيوم.</li><li>عانيت مؤخراً من الإسهال بعد تناول مضاداً حيوياً. إذا عانيت في أي وقت مضى من مشاكل في أمعائك، وخصوصاً التهاب القولون (التهاب الأمعاء).</li><li>كنت تعاني من مشاكل في الكبد أو الكلى (انظر القسم 4).</li><li>كنت تعاني من حصى المرارة أو حصى الكلى.</li><li>كنت تعاني من أمراض أخرى، مثل فقر الدم الانحلالي (انخفاض في خلايا الدم الحمراء التي قد تجعل بشرتك شاحبة بلون أصفر وتسبب ضعفاً عاماً أو ضيقاً في التنفس).</li><li>كنت تسير على حمية قليلة الصوديوم.</li><li>كنت تعاني أو سبق لك أن عانيت من أي مجموعة من الأعراض التالية: طفح واحمرار الجلد ووجود بثور على الشفتين، العينين والفم وتقشر الجلد وحمى شديدة وأعراض تشبه الأنفلونزا وزيادة مستويات إنزيمات الكبد في فحوصات الدم وزيادة في أحد أنواع خلايا الدم البيضاء (كثرة اليوزينيات) وتضخم الغدد الليمفاوية (علامات ردود فعل جلدية حادة، انظر أيضاً القسم 4 &quot;الآثار الجانبية المحتملة&quot;).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> كنت بحاجة لإجراء فحص الدم أو البول</strong></p><p dir="RTL">قد تحتاج إلى إجراء فحوصات الدم بانتظام إذا تم إعطاؤك سيفاكسون لفترة طويلة. يمكن أن يؤثر سيفاكسون على نتائج فحوصات البول لفحص السكر وفحص الدم المعروف باسم فحص كومبز.إذا كنت ستقوم بفحوصات:</p><ul dir="rtl"><li>أخبر الشخص الذي سيأخذ العينة أنه قد تم إعطاؤك سيفاكسون.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مصاب بالسكري أو تحتاج لمراقبة كمية الغلوكوز في الدم يجب عليك عدم استخدام أجهزة معينة لمراقبة كمية الغلوكوز في الدم والتي من الممكن أن تقدر غلوكوز الدم بطريقة غير صحيحة خلال فترة تناولك سيفترياكسون، إذا كنت تستخدم أجهزة كهذه تأكد من تعليمات الاستخدام وأخبر طبيبك، الصيدلي أو الممرض. يجب استخدام طرق بديلة إذا كان ذلك ضرورياً</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل أن يعطى سيفاكسون لطفلك، إذا:</p><ul dir="rtl"><li>أعطي/ أعطيت في الآونة الأخيرة أو سيعطى منتجات تحتوي على الكالسيوم في الوريد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسيفاكسون</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أية أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية على وجه الخصوص</p><ul dir="rtl"><li>نوع من المضادات الحيوية والمسمى أمينوغليكوزيد.</li><li>نوع من المضادات الحيوية والمسمى الكلورامفينيكول (يستخدم لعلاج الالتهابات، وخاصة في العينين).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">يرجى استشارة طبيبك إذا كنت حاملاً أو مرضعة، تعتقدين أنك حاملاً أو تخططين لذلك. استشيري طبيبك من أجل النصيحة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يقوم الطبيب بتقييم مدى الاستفادة من علاجك بسيفاكسون مقابل المخاطر التي قد يتعرض لها طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يتسبب سيفاكسون بشعور بالدوار. إذا شعرت بالدوار، لا تقم بالقيادة أو استخدام أي أدوات أو آلات. تحدث مع طبيبك إذا واجهت هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سيفاكسون على الصوديوم</strong><strong> </strong></p><p dir="RTL">يحتوي سيفاكسون على الصوديوم. تحتوي كل زجاجة من سيفاكسون 500 ملغم و1000 ملغم مسحوق للحل للحقن على 41.492 ملغم أو 82.984 ملغم صوديوم (المكون الأساسي في الطبخ/ملح الطعام)؛ على التوالي. وهذا يكافئ 2,1% أو 4.1%؛ على التوالي من الجرعة اليومية القصوى الموصى بها من الصوديوم للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادة ما يعطى سيفاكسون من قبل طبيب أو ممرضة. يمكن أن يعطى بالتنقيط (التسريب في الوريد) أو بحقنة مباشرة في الوريد.</p><p dir="RTL"><br />تحضر جرعة سيفاكسون من قبل الطبيب أو الصيدلي أو الممرضة ولن يخلط مع أو يعطى لك في نفس الوقت الذي تعطى فيه حقن أخرى تحتوي على الكالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الاعتيادية:</strong></p><p dir="RTL">سوف يقرر الطبيب الجرعة الصحيحة المناسبة لك من سيفاكسون. تعتمد الجرعة على شدة ونوع العدوى، وما إذا كنت تتناول أي من المضادات الحيوية الأخرى، وعلى وزنك، وعمرك؛ وصحة عمل الكليتين والكبد لديك. سيعتمد عدد الأيام أو الأسابيع التي سيعطى لك سيفاكسون فيها على نوع العدوى التي لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>البالغين</em><em> والمسنين والأطفال الذين يبلغون من العمر 12 سنة فما فوق مع والذين يزنون أكثر من أو يساوي 50 كغم:</em></p><ul dir="rtl"><li>2000-1000 ملغم مرة واحدة يومياً تبعا لشدة ونوع العدوى. إذا كنت تعاني من عدوى شديدة، فسوف يعطيك طبيبك جرعة أعلى (تصل إلى 4000 ملغم مرة واحدة في اليوم). إذا كانت الجرعة اليومية أعلى من 2000 ملغم، فقد تتلقاها كجرعة واحدة مرة واحدة في اليوم أو كجرعتين منفصلتين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال حديثي الولادة</em><em> والرضع والأطفال الذين تتراوح أعمارهم بين 15 يوم إلى 12 سنة والذين يزنون أقل من 50 كغم:</em></p><ul dir="rtl"><li>80-50 ملغم من سيفاكسون لكل كيلوغرام من وزن الجسم مرة واحدة يومياً تبعا لشدة ونوع العدوى. إذا كان لديه عدوى شديدة، فسوف يعطيه الطبيب جرعة أعلى تصل إلى 100 ملغم لكل كيلوغرام من وزن الجسم لكمية أقصاها 4000 ملغم مرة واحدة يومياً. إذا كانت الجرعة اليومية أكبر من 2000 ملغم، فقد تعطى كجرعة واحدة مرة واحدة في اليوم أو كجرعتين منفصلتين.</li><li>يعطى الأطفال الذين يزنون 50 كغم أو أكثر الجرعة المعتادة للبالغين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال حديثي الولادة</em><em> (0-14 يوم)</em></p><ul dir="rtl"><li>50-20 ملغم من سيفاكسون لكل كيلوغرام من وزن الجسم مرة واحدة يوميا تبعاً لشدة ونوع العدوى.</li><li>الجرعة اليومية القصوى لا يجب أن تكون أكثر من 50 ملغم لكل كيلوغرام من وزن الطفل.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>المرضى الذين يعانون من</em><em> مشاكل في الكبد والكلى</em></p><p dir="RTL">قد تعطى جرعة مختلفة عن الجرعة المعتادة. سوف يقرر طبيبك كمية سيفاكسون التي تحتاجها وسوف يقوم بفحصك بدقة وفق شدة مرض الكبد والكلى لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك سيفاكسون أكثر من اللازم</strong></p><p dir="RTL">إذا أعطيت جرعة زائدة بالخطأ. اتصل مع طبيبك أو أقرب مركز طوارئ على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام سيفاكسون</strong></p><p dir="RTL">إذا فوتّ حقنة، يجب أن تأخذها في أقرب وقت ممكن. ومع ذلك، إذا كنت على مقربة من الجرعة القادمة، فتجاوز الحقنة التي فوتها. لا تأخذ جرعة مضاعفة (حقنتين في نفس الوقت) لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام سيفاكسون</strong></p><p dir="RTL">لا تتوقف عن استخدام سيفاكسون ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء. قد تحصل الأعراض الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب العلاج بسيفترياكسون انخفاض الوعي وحدوث حركات غير طبيعية وتهيج وتشنجات في حالات نادرة، وبخاصة مع المرضى كبار السن الذين يعانون من مشكلات خطيرة في الكُلى أو الجهاز العصبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>رد فعل تحسسي شديد</strong><strong> (غير معروف، لا يمكن تقدير التكرار من البيانات المتاحة).</strong></p><p dir="RTL">إذا عانيت من رد فعل تحسسي شديد، أخبر الطبيب على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويمكن أن تشتمل أعراض رد الفعل التحسسي على:</p><ul dir="rtl"><li>تورم مفاجئ في الوجه، الحلق، الشفاه أو الفم. يمكن أن يجعل ذلك التنفس أو البلع صعباً.</li><li>تورم مفاجئ في اليدين، القدمين والكاحلين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ردود فعل جلدية حادة (</strong><strong>غير معروف، لا يمكن تقدير التكرار من البيانات المتاحة</strong><strong>) </strong></p><p dir="RTL">أبلغ الطبيب على الفور إذا كنت تعاني من طفح جلدي حاد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تشمل العلامات:</p><ul dir="rtl"><li>طفح جلدي حاد يتطور سريعاً مع ظهور بثور أو تقشر في الجلد، وقد تظهر البثور أيضاً بالفم (متلازمة ستيفنز جونسون وتقشر الأنسجة المتموتة البشروية التسممي)</li><li>الإصابة بأي مجموعة من الأعراض التالية: انتشار الطفح الجلدي وارتفاع درجة حرارة الجسم وارتفاع إنزيمات الكبد وتشوهات دموية<strong> </strong>(كثرة اليوزينيات) وتضخم العقد الليمفاوية ووجود مشكلات في أعضاء الجسم الأخرى (التفاعل الدوائي مع اليوزينيات ومع أعراض شاملة والمعروفة كذلك باسم متلازمة فرط الحساسية للدواء).</li><li>تفاعل جاريش هركسايمر الذي يسبب حمى وقشعريرة وصداع وألم بالعضلات وطفح جلدي يكون في العادة ذاتي الشفاء. يحدث هذا بعد فترة قصيرة من بدء العلاج بسفترياكسون لحالات العدوى بالبكتيريا الملتوية مثل داء لايم.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية المحتملة الأخرى:</em></strong></p><p dir="RTL"><strong>شائعة </strong>(<strong>قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص</strong><strong>)</strong></p><ul dir="rtl"><li>شذوذ في خلايا الدم البيضاء (مثل انخفاض الكريات البيضاء وزيادة الحمضات) وفي الصفائح الدموية (نقص الصفيحات).</li><li>براز رخو أو إسهال.</li><li>تغيرات في نتائج فحوصات الدم لوظائف الكبد.</li><li>الطفح الجلدي.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (</strong><strong>قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص</strong><strong>)</strong></p><ul dir="rtl"><li>العدوى الفطرية (على سبيل المثال، القلاع).</li><li>انخفاض في عدد خلايا الدم البيضاء (المحببات).</li><li>انخفاض في عدد خلايا الدم الحمراء (فقر الدم).</li><li>مشاكل في طريقة تجلط الدم. يمكن أن تشمل الأعراض حدوث كدمات بسهولة وألم وتورم في المفاصل.</li><li>صداع.</li><li>دوخة.</li><li>الشعور بالغثيان أو التقيؤ.</li><li>الحكة.</li><li>ألم أو شعور بحرقة على طول الوريد حيث تم إعطاء سيفترياكسون. بثور، احمرار عميق أو طفح، مناطق محروقة، ألم، تهيج وحكة في موضع الحقن.</li><li>ارتفاع في درجة الحرارة (حمى).</li><li>اختلال في فحص وظائف الكلى (زيادة الكرياتينين في الدم).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (</strong><strong>قد تؤثر فيما يصل إلى شخص من بين كل 1000 شخص</strong><strong>)</strong></p><ul dir="rtl"><li>التهاب الأمعاء الغليظة (القولون). وتشتمل الأعراض الإسهال، وعادة ما يكون مصحوباً بالدم والمخاط، وآلام في المعدة وحمى.</li><li>صعوبة في التنفس (تشنج قصبي).</li><li>طفح جلدي عقدي (الشرى) والذي قد يغطي مساحة كبيرة من الجسم، الشعور بالحكة والتورم.</li><li>الدم أو السكر في البول.</li><li>وذمة (تراكم السوائل).</li><li>الرعاش.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة</strong>)</p><ul dir="rtl"><li>عدوى ثانوية قد لا تستجيب للمضادات الحيوية الموصوفة سابقاً.</li><li>شكل من أشكال فقر الدم حيث يتم تدمير خلايا الدم الحمراء (فقر الدم الانحلالي).</li><li>انخفاض حاد في خلايا الدم البيضاء (ندرة المحببات).</li><li>تشنجات.</li><li>دوار.</li><li>التهاب البنكرياس. وتشتمل الأعراض آلاماً حادةً في المعدة تمتد إلى الظهر.</li><li>التهاب بطانة الفم المخاطية (التهاب الفم).</li><li>التهاب اللسان. وتشتمل الأعراض التورم والاحمرار وألم حاد في اللسان.</li><li>مشاكل في المرارة و/أو الكبد والتي قد تسبب الألم، الشعور بالغثيان، التقيؤ، اصفرار الجلد، حكة، بول داكن بشكل غير عادي وبراز بلون الطين.</li><li>مشاكل عصبية قد تحدث لدى حديثي الولادة ممن يعانون من اليرقان الشديد (اليرقان النووي).</li><li>مشاكل في الكلى ناتجة عن ترسبات سيفترياكسون الكالسيوم. قد يكون هناك ألم عند التبول أو انخفاض في إنتاج البول.</li><li>نتيجة إيجابية خاطئة في فحص كومبز (فحص بعض مشاكل الدم).</li><li>نتيجة إيجابية خاطئة لوجود الجلاكتوز في الدم (بناء الجلاكتوز بطريقة غير طبيعية).</li><li>قد يتداخل سيفاكسون مع بعض أنواع فحوصات السكر في الدم- يرجى مراجعة طبيبك.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL" style="text-align:justify">راجع طبيبك أو الصيدلي إذا ساءت أية من هذه الآثار الجانبية أو لاحظت ظهور أية آثار جانبية غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 25&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي خلال فترة الاستخدام للمستحضر المحضر والمحلول المخفف لمدة لا تقل عن 6 ساعات عند درجة حرارة 25&deg; مئوية أو أقل أو لمدة 24 ساعة عند درجة حرارة 2-8&deg; مئوية.</p><p dir="RTL">من وجهة النظر الميكروبيولوجية، يجب استخدام المستحضر على الفور. في حال عدم استخدامه على الفور، تقع مسؤولية فترات التخزين أثناء الاستخدام وظروف التخزين قبل الاستخدام على المستخدم ولا يجب أن تكون المدة أطول من المدة المذكورة أعلاه في دراسات الاستقرار الكيميائي والفيزيائي خلال فترة الاستخدام.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيفترياكسون الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة من سيفاكسون 500 ملغم مسحوق للحل للحقن على 596.5 ملغم سيفترياكسون الصوديوم يكافئ 500 ملغم سيفترياكسون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة من سيفاكسون 1000 ملغم مسحوق للحل للحقن على 1193 ملغم سيفترياكسون الصوديوم يكافئ 1000 ملغم سيفترياكسون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوجد مكونات أخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">سيفاكسون 500 ملغم مسحوق للحل للحقن هو مسحوق بلوري لونه أبيض تقريباً أو أصفر في زجاجات عديمة اللون مع أغطية ذات لون أزرق نيلي.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">سيفاكسون 1000 ملغم مسحوق للحل للحقن هو مسحوق بلوري لونه أبيض تقريباً إلى أصفر في زجاجات عديمة اللون مع أغطية ذات لون أبيض.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بعد الحلّ، يتراوح لون المحلول من الأصفر الباهت إلى اللون الكهرماني.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة </strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم <img src="data:image/png;base64,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" alt="" width="126" height="26" vspace="0" hspace="0" border="0" style="width:126px;height:26px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />، فارفانسا<br />2705-906 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2023/11؛ رقم النسخة SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cefaxon 1000 mg Powder for Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of Cefaxon 1000 mg Powder for Solution for Injection contains 1193 mg ceftriaxone sodium equivalent to 1000 mg ceftriaxone.

Excipient with known effect: Sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection.

Almost white or yellowish crystalline powder.

After reconstitution, the color of solutions ranges from pale yellow to amber.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefaxon is indicated for the treatment of the following infections in adults and children including term neonates (from birth):</p><ul><li>Bacterial Meningitis</li><li>Community acquired pneumonia</li><li>Hospital acquired pneumonia</li><li>Intra-abdominal infections</li><li>Complicated urinary tract infections (including pyelonephritis)</li><li>Infections of bones and joints</li><li>Complicated skin and soft tissue infections</li><li>Syphilis</li><li>Bacterial endocarditis</li></ul><p>&nbsp;</p><p>Cefaxon may be used:</p><ul><li>For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults</li><li>For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age</li><li>For Pre-operative prophylaxis of surgical site infections</li><li>In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection</li><li>In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above</li></ul><p>&nbsp;</p><p>Cefaxon should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4).</p><p>&nbsp;</p><p>Consideration should be given to official guidelines on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient.</p><p>&nbsp;</p><p>The doses recommended in the tables below are the generally recommended doses in these indications. In particularly severe cases, doses at the higher end of the recommended range should be considered.</p><p>&nbsp;</p><p><u>Adults and children over 12 years of age (&ge; 50&nbsp;kg)</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ceftriaxone </strong><strong>Dosage*</strong></p></td><td style="vertical-align:top"><p><strong>Treatment frequency**</strong></p></td><td style="vertical-align:top"><p><strong>Indications</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>1000-2000 mg</p></td><td rowspan="4" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Acute exacerbations of chronic obstructive pulmonary disease</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>2000 mg</p></td><td rowspan="3" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Hospital acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Infections of bones and joints</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>2000-4000 mg</p></td><td rowspan="3" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial endocarditis</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr></tbody></table><p>* In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>** Twice daily (12 hourly) administration may be considered where doses greater than 2000 mg daily are administered.</p><p>&nbsp;</p><p>Indications for adults and children over 12 years of age (&ge; 50 kg) that require specific dosage schedules:</p><p><em>Pre-operative prophylaxis of surgical site infections</em></p><p>2000 mg as a single pre-operative dose.</p><p>&nbsp;</p><p><em>Syphilis</em></p><p>The generally recommended doses are 500 mg-1000 mg once daily increased to 2000 mg once daily for neurosyphilis for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on limited data. National or local guidance should be taken into consideration.</p><p>&nbsp;</p><p><em>Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])</em></p><p>2000 mg once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><em>Neonates, infants and children 15 days to 12 years of age (&lt; 50&nbsp;kg)</em></p><p>For children with bodyweight of 50 kg or more, the usual adult dosage should be given.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ceftriaxone dosage*</strong></p></td><td style="vertical-align:top"><p><strong>Treatment frequency**</strong></p></td><td style="vertical-align:top"><p><strong>Indications</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>50-80 mg/kg</p></td><td rowspan="4" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Hospital acquired pneumonia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>50-100 mg/kg (Max 4000 mg)</p></td><td rowspan="3" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Infections of bones and joints</p></td></tr><tr><td style="vertical-align:top"><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td style="vertical-align:top"><p>80-100 mg/kg (max 4000 mg)</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>100 mg/kg (max 4000 mg)</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Bacterial endocarditis</p></td></tr></tbody></table><p>* In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>** Twice daily (12 hourly) administration may be considered where doses greater than 2000 mg daily are administered.</p><p>&nbsp;</p><p>Indications for infants and children 15 days to 12 years (&lt; 50 kg) that require specific dosage schedules:</p><p><em>Pre-operative prophylaxis of surgical site infections</em></p><p>50-80 mg/kg as a single pre-operative dose.</p><p>&nbsp;</p><p><em>Syphilis</em></p><p>The generally recommended doses are 75-100 mg/kg (max 4000 mg) once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.</p><p>&nbsp;</p><p><em>Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])</em></p><p>50&ndash;80 mg/kg once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.</p><p>&nbsp;</p><p><em>Neonates 0-14 days</em></p><p>Ceftriaxone is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ceftriaxone dosage*</strong></p></td><td style="vertical-align:top"><p><strong>Treatment frequency</strong></p></td><td style="vertical-align:top"><p><strong>Indications</strong></p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>20-50 mg/kg</p></td><td rowspan="7" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Hospital acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Infections of bones and joints</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>50 mg/kg</p></td><td rowspan="2" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial endocarditis</p></td></tr></tbody></table><p>* In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>A maximum daily dose of 50 mg/kg should not be exceeded.</p><p>&nbsp;</p><p>Indications for infants and children 15 days to 12 years (&lt; 50 kg) that require specific dosage schedules:</p><p>&nbsp;</p><p><em>Pre-operative prophylaxis of surgical site infections</em></p><p>20-50 mg/kg as a single pre-operative dose.</p><p>&nbsp;</p><p><em>Syphilis</em></p><p>The generally recommended dose is 50 mg/kg once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.</p><p>&nbsp;</p><p><u>Duration of therapy</u></p><p>The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of Cefaxon should be continued for 48 - 72 hours after the patient has become afebrile or evidence of bacterial eradication has been achieved.</p><p>&nbsp;</p><p><u>Older people</u></p><p>The dosages recommended for adults require no modification in older people provided that renal and hepatic function is satisfactory.</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p>Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment provided renal function is not impaired.</p><p>&nbsp;</p><p>There are no study data in patients with severe hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>In patients with impaired renal function, there is no need to reduce the dosage of Cefaxon provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine clearance &lt; 10 ml/min) should the Cefaxon dosage not exceed 2000 mg daily.</p><p>In patients undergoing dialysis no additional supplementary dosing is required following the dialysis.</p><p>Ceftriaxone is not removed by peritoneal- or haemodialysis. Close clinical monitoring for safety and efficacy is advised.</p><p>&nbsp;</p><p><u>Patients with severe hepatic and renal impairment</u></p><p>In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p><u>Intravenous administration</u></p><p>Cefaxon can be administered by intravenous infusion over at least 30 minutes (preferred route) or by slow intravenous injection over 5 minutes. Intravenous intermittent injection should be given over 5 minutes preferably in larger veins. Intravenous doses of 50 mg/kg or more in infants and children up to 12 years of age should be given by infusion. In neonates, intravenous doses should be given over 60 minutes to reduce the potential risk of bilirubin encephalopathy (see section 4.3 and 4.4). Intramuscular administration should be considered when the intravenous route is not possible or less appropriate for the patient. For doses greater than 2000 mg intravenous administration should be used.</p><p>&nbsp;</p><p>Ceftriaxone is contraindicated in neonates (&le; 28 days) if they require (or are expected to require) treatment with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition, because of the risk of precipitation of ceftriaxone-calcium (see section 4.3).</p><p>&nbsp;</p><p>Diluents containing calcium, (e.g. Ringer&#39;s solution or Hartmann&#39;s solution), should not be used to reconstitute Cefaxon vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Cefaxon is mixed with calcium-containing solutions in the same intravenous administration line. Therefore, Cefaxon and calcium-containing solutions must not be mixed or administered simultaneously (see sections 4.3, 4.4 and 6.2).</p><p>&nbsp;</p><p>For pre-operative prophylaxis of surgical site infections, Cefaxon should be administered 30-90 minutes prior to surgery.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to ceftriaxone or to any other cephalosporin.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

Cefaxon is contraindicated in:
•	Premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age)*
•	Full-term neonates (up to 28 days of age):
-	With hyperbilirubinaemia, jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which bilirubin binding is likely to be impaired*
-	If they require (or are expected to require) intravenous calcium treatment, or calcium-containing infusions due to the risk of precipitation of a ceftriaxone-calcium salt (see sections 4.4, 4.8 and 6.2).

* In vitro studies have shown that ceftriaxone can displace bilirubin from its serum albumin binding sites leading to a possible risk of bilirubin encephalopathy in these patients.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Hypersensitivity reactions</em></strong></p><p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported (see section 4.8). In case of severe hypersensitivity reactions, treatment with Cefaxon must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftriaxone, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if Cefaxon is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (Stevens Johnson syndrome or Lyell&#39;s syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS)) which can be life-threatening or fatal have been reported in association of ceftriaxone treatment; however, the frequency of these events is not known (see section 4.8).</p><p>&nbsp;</p><p><u>Interaction with calcium containing products</u></p><p>Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term neonates aged less than 1 month have been described. At least one of them had received ceftriaxone and calcium at different times and through different intravenous lines. In the available scientific data, there are no reports of confirmed intravascular precipitations in patients, other than neonates, treated with ceftriaxone and calcium-containing solutions or any other calcium-containing products.&nbsp;<em>In vitro </em>studies demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium compared to other age groups.</p><p>&nbsp;</p><p>In patients of any age Cefaxon must not be mixed or administered simultaneously with any calcium-containing intravenous solutions, even via different infusion lines or at different infusion sites. However, in patients older than 28 days of age Cefaxon and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. In patients requiring continuous infusion with calcium-containing total parenteral nutrition (TPN) solutions, healthcare professionals may wish to consider the use of alternative antibacterial treatments which do not carry a similar risk of precipitation. If the use of Cefaxon is considered necessary in patients requiring continuous nutrition, TPN solutions and Cefaxon can be administered simultaneously, albeit via different infusion lines at different sites. Alternatively, infusion of TPN solution could be stopped for the period of Cefaxon<strong> </strong>infusion and the infusion lines flushed between solutions (see sections 4.3, 4.8, 5.2 and 6.2).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Safety and effectiveness of ceftriaxone<strong> </strong>in neonates, infants and children have been established for the dosages described under Posology and Method of Administration (see section 4.2). Studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin.</p><p>&nbsp;</p><p>Cefaxon is contraindicated in premature and full-term neonates at risk of developing bilirubin encephalopathy (see section 4.3).</p><p>&nbsp;</p><p><strong><em>Immune mediated haemolytic anaemia</em></strong></p><p>An immune mediated haemolytic anaemia has been observed in patients receiving cephalosporin class antibacterials including ceftriaxone<strong> </strong>(see section 4.8). Severe cases of haemolytic anaemia, including fatalities, have been reported during ceftriaxone<strong> </strong>treatment in both adults and children.</p><p>&nbsp;</p><p>If a patient develops anaemia while on Cefaxon, the diagnosis of a cephalosporin<strong><em>-</em></strong>associated anaemia should be considered and Cefaxon discontinued until the aetiology is determined.</p><p>&nbsp;</p><p><u>Long term treatment</u></p><p>During prolonged treatment complete blood count should be performed at regular intervals.</p><p>&nbsp;</p><p><u>Colitis/Overgrowth of non-susceptible microorganisms</u></p><p>Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all antibacterial agents, including ceftriaxone, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of Cefaxon (see section 4.8). Discontinuation of therapy with Cefaxon and the administration of specific treatment for&nbsp;<em>Clostridium difficile</em>&nbsp;should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>&nbsp;</p><p>Superinfections with non-susceptible micro-organisms may occur as with other antibacterial agents.</p><p>&nbsp;</p><p><u>Severe renal and hepatic insufficiency</u></p><p>In severe renal and hepatic insufficiency, close clinical monitoring for safety and efficacy is advised (see section 4.2).</p><p>&nbsp;</p><p><u>Interference with serological testing</u></p><p>Interference with Coombs tests may occur, as Cefaxon<strong> </strong>may lead to false-positive test results.</p><p>&nbsp;</p><p>Cefaxon<strong> </strong>can also lead to false-positive test results for galactosaemia (see section 4.8).</p><p>&nbsp;</p><p>Non-enzymatic methods for the glucose determination in urine may give false-positive results. Urine glucose determination during therapy with Cefaxon<strong> </strong>should be done enzymatically (see section 4.8).</p><p>&nbsp;</p><p>The presence of ceftriaxone may falsely lower estimated blood glucose values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>Cefaxon contains sodium. Each vial of Cefaxon 1000 mg Powder for Solution for Injection contains 82.984 mg sodium (main component of cooking/table salt). This is equivalent to 4.1% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p><u>Antibacterial spectrum</u></p><p>Ceftriaxone has a limited spectrum of antibacterial activity and may not be suitable for use as a single agent for the treatment of some types of infections unless the pathogen has already been confirmed (see section 4.2). In polymicrobial infections, where suspected pathogens include organisms resistant to Cefaxon, administration of an additional antibiotic should be considered.</p><p>&nbsp;</p><p><u>Biliary lithiasis</u></p><p>When shadows are observed on sonograms, consideration should be given to the possibility of precipitates of calcium-ceftriaxone. Shadows, which have been mistaken for gallstones, have been detected on sonograms of the gallbladder and have been observed more frequently at ceftriaxone doses of 1000 mg per day and above. Caution should be particularly considered in the paediatric population. Such precipitates disappear after discontinuation of ceftriaxone therapy. Rarely precipitates of calcium-ceftriaxone have been associated with symptoms. In symptomatic cases, conservative nonsurgical management is recommended and discontinuation of ceftriaxone treatment should be considered by the physician based on specific benefit risk assessment (see section 4.8).</p><p>&nbsp;</p><p><u>Biliary stasis</u></p><p>Cases of pancreatitis, possibly of biliary obstruction aetiology, have been reported in patients treated with ceftriaxone<strong> </strong>(see section 4.8). Most patients presented with risk factors for biliary stasis and biliary sludge e.g. preceding major therapy, severe illness and total parenteral nutrition. A trigger or cofactor of ceftriaxone-related biliary precipitation cannot be ruled out.</p><p>&nbsp;</p><p><u>Renal lithiasis</u></p><p>Cases of renal lithiasis have been reported, which is reversible upon discontinuation of ceftriaxone (see section 4.8). In symptomatic cases, sonography should be performed. Use in patients with history of renal lithiasis or with hypercalciuria should be considered by the physician based on specific benefit risk assessment.</p><p>&nbsp;</p><p><u>Jarisch-Herxheimer reaction (JHR)</u></p><p>Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction (JHR) shortly after ceftriaxone treatment is started. JHR is usually a self - limiting condition or can be managed by symptomatic treatment. The antibiotic treatment should not be discontinued if such reaction occurs.</p><p>&nbsp;</p><p><u>Encephalopathy</u></p><p>Encephalopathy has been reported with the use of ceftriaxone (see section 4.8), particularly in elderly patients with severe renal impairment (see section 4.2) or central nervous system disorders. If ceftriaxone-associated encephalopathy is suspected (e.g. decreased level of consciousness, altered mental state, myoclonus, convulsions), discontinuation of Cefaxon should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Calcium-containing diluents, such as Ringer&#39;s solution or Hartmann&#39;s solution, should not be used to reconstitute Cefaxon vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Cefaxon is mixed with calcium-containing solutions in the same intravenous administration line. Cefaxon must not be administered simultaneously with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Cefaxon and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid.&nbsp;<em>In vitro</em>&nbsp;studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see sections 4.2, 4.3, 4.4, 4.8 and 6.2).</p><p>&nbsp;</p><p>Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of bleeding. It is recommended that the International Normalised Ratio (INR) is monitored frequently and the posology of the anti-vitamin K drug adjusted accordingly, both during and after treatment with Cefaxon (see section 4.8).</p><p>&nbsp;</p><p>There is conflicting evidence regarding a potential increase in renal toxicity of aminoglycosides when used with cephalosporins. The recommended monitoring of aminoglycoside levels (and renal function) in clinical practice should be closely adhered to in such cases.</p><p>&nbsp;</p><p>In an&nbsp;<em>in-vitro</em>&nbsp;study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone. The clinical relevance of this finding is unknown.</p><p>&nbsp;</p><p>There have been no reports of an interaction between ceftriaxone and oral calcium-containing products.</p><p>&nbsp;</p><p>In patients treated with ceftriaxone, the Coombs&#39; test may lead to false-positive test results.</p><p>&nbsp;</p><p>Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia.</p><p>&nbsp;</p><p>Likewise, non-enzymatic methods for glucose determination in urine may yield false-positive results. For this reason, glucose level determination in urine during therapy with Cefaxon should be carried out enzymatically.</p><p>&nbsp;</p><p>No impairment of renal function has been observed after concurrent administration of large doses of ceftriaxone and potent diuretics (e.g. furosemide).</p><p>&nbsp;</p><p>Simultaneous administration of probenecid does not reduce the elimination of ceftriaxone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Ceftriaxone crosses the placental barrier. There are limited amounts of data from the use of ceftriaxone in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal, perinatal and postnatal development (see section 5.3). Ceftriaxone should only be administered during pregnancy and in particular in the first trimester of pregnancy if the benefit outweighs the risk.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Ceftriaxone is excreted into human milk in low concentrations but at therapeutic doses of ceftriaxone no effects on the breastfed infants are anticipated. However, a risk of diarrhoea and fungal infection of the mucous membranes cannot be excluded. The possibility of sensitisation should be taken into account. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ceftriaxone therapy, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Reproductive studies have shown no evidence of adverse effects on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During treatment with Cefaxon, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8). Patients should be cautious when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.</p><p>&nbsp;</p><p>Data to determine the frequency of ceftriaxone ADRs was derived from clinical trials.</p><p>&nbsp;</p><p>The following convention has been used for the classification of frequency:</p><p>Very common (&ge; 1/10)</p><p>Common (&ge; 1/100 - &lt; 1/10)</p><p>Uncommon (&ge; 1/1000 - &lt; 1/100)</p><p>Rare (&ge; 1/10000 - &lt; 1/1000)</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known<sup>&nbsp;a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Genital fungal infection</p></td><td style="vertical-align:top"><p>Pseudo-membranous colitis<sup>b</sup></p></td><td style="vertical-align:top"><p>Superinfection<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Eosinophilia Leucopenia</p><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Granulocytopenia</p><p>Anaemia</p><p>Coagulopathy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haemolytic anaemia<sup>b</sup></p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic shock</p><p>Anaphylactic reaction</p><p>Anaphylactoid reaction</p><p>Hypersensitivity<sup>b</sup></p><p>Jarisch-Herxheimer reaction<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Encephalopathy</p></td><td style="vertical-align:top"><p>Convulsion</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea<sup>b</sup></p><p>Loose stools</p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis<sup>b</sup></p><p>Stomatitis</p><p>Glossitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gall bladder precipitationb</p><p>Kernicterus</p><p>Hepatitisc</p><p>Hepatitis cholestaticb,c</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Stevens Johnson Syndrome<sup>b</sup></p><p>Toxic epidermal necrolysis<sup>b</sup></p><p>Erythema multiforme</p><p>Acute generalised exanthematous pustulosis</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p><p>Glycosuria</p></td><td style="vertical-align:top"><p>Oliguria</p><p>Renal precipitation (reversible)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Phlebitis</p><p>Injection site reaction</p><p>Pyrexia</p></td><td style="vertical-align:top"><p>Oedema</p><p>Chills</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Coombs test false positive<sup>b</sup></p><p>Galactosaemia test false positive<sup>b</sup></p><p>Non enzymatic methods for glucose determination false positive<sup>b</sup></p></td></tr></tbody></table><p><sup>a&nbsp;</sup>Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.</p><p><sup>b</sup>&nbsp;See section 4.4</p><p>c&nbsp;Usually reversible upon discontinuation of ceftriaxone</p><p>&nbsp;</p><p><strong><em>Description of selected adverse reactions</em></strong></p><p><em>Infections and infestations</em></p><p>Reports of diarrhoea following the use of ceftriaxone may be associated with&nbsp;<em>Clostridium difficile</em>. Appropriate fluid and electrolyte management should be instituted (see section 4.4).</p><p>&nbsp;</p><p><em>Ceftriaxone-calcium salt precipitation</em></p><p>Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged &lt; 28 days) who had been treated with intravenous ceftriaxone and calcium. Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).</p><p>&nbsp;</p><p>Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children treated with high doses (e.g. &ge; 80 mg/kg/day or total doses exceeding 10 grams) and who have other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually reversible upon discontinuation of ceftriaxone (see section 4.4).</p><p>&nbsp;</p><p>Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose. In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30% in some studies. The incidence appears to be lower with slow infusion (20 - 30 minutes). This effect is usually asymptomatic, but the precipitations have been accompanied by clinical symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is recommended in these cases. Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4).</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In overdose, the symptoms of nausea, vomiting and diarrhoea can occur. Ceftriaxone concentrations cannot be reduced by haemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdose should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Third-generation cephalosporins, ATC code: J01DD04</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Mode of action</em></strong></p><p>Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p>&nbsp;</p><p><strong><em>Resistance</em></strong></p><p>Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms:</p><ul><li>Hydrolysis by beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), carbapenemases and Amp C enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species.</li><li>Reduced affinity of penicillin-binding proteins for ceftriaxone.</li><li>Outer membrane impermeability in Gram-negative organisms.</li><li>Bacterial efflux pumps.</li></ul><p>&nbsp;</p><p><strong><em>Susceptibility testing breakpoints</em></strong></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Dilution Test</strong></p><p><strong>(MIC, mg/L)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Susceptible</strong></p></td><td style="vertical-align:bottom"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td><p>&le; 1</p></td><td><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em>&nbsp;spp.</p></td><td><p>a.</p></td><td><p>a.</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>spp.</p><p><em>(</em>Groups A, B, C and G)</p></td><td><p>b.</p></td><td><p>b.</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td><p>&le; 0.5<sup>c.</sup></p></td><td><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p>Viridans group&nbsp;<em>Streptococci</em></p></td><td><p>&le;0.5</p></td><td><p>&gt;0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td><p>&le; 0.12<sup>c.</sup></p></td><td><p>&gt; 0.12</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td><p>&le; 1</p></td><td><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td><td><p>&le; 0.12</p></td><td><p>&gt; 0.12</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis</em></p></td><td><p>&le; 0.12<sup>&nbsp;c.</sup></p></td><td><p>&gt; 0.12</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related</p></td><td><p>&le; 1<sup>d.</sup></p></td><td><p>&gt; 2</p></td></tr></tbody></table><p>a. Susceptibility inferred from cefoxitin susceptibility.</p><p>b. Susceptibility inferred from penicillin susceptibility.</p><p>c. Isolates with a ceftriaxone MIC above the susceptible breakpoint are rare and, if found, should be re-tested and, if confirmed, should be sent to a reference laboratory.</p><p>d. Breakpoints apply to a daily intravenous dose of 1000 mg x 1 and a high dose of at least 2000 mg x 1.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Clinical efficacy against specific pathogens</em></strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftriaxone in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gram-positive aerobes</em></strong></p><p><em>Staphylococcus aureus</em>&nbsp;(methicillin-susceptible)<sup>&pound;</sup></p><p>Staphylococci coagulase-negative (methicillin-susceptible)<sup>&pound;</sup></p><p><em>Streptococcus pyogenes</em>&nbsp;(Group A)</p><p><em>Streptococcus agalactiae</em>&nbsp;(Group B)</p><p><em>Streptococcus pneumoniae</em></p><p>Viridans Group&nbsp;<em>Streptococci</em></p><p><strong><em>Gram-negative aerobes</em></strong></p><p><em>Borrelia burgdorferi</em></p><p><em>Haemophilus influenzae</em></p><p><em>Haemophilus parainfluenzae</em></p><p><em>Moraxella</em>&nbsp;<em>catarrhalis</em></p><p><em>Neisseria</em>&nbsp;<em>gonorrhoea</em></p><p><em>Neisseria meningitidis</em></p><p><em>Proteus</em>&nbsp;<em>mirabilis</em></p><p><em>Providencia</em>&nbsp;spp.</p><p><em>Treponema pallidum</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gram-positive aerobes</em></strong></p><p><em>Staphylococcus epidermidis<sup>+</sup></em></p><p><em>Staphylococcus haemolyticus<sup>+</sup></em></p><p><em>Staphylococcus hominis<sup>+</sup></em></p><p><strong><em>Gram-negative aerobes</em></strong></p><p><em>Citrobacter</em>&nbsp;<em>freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli<sup>%</sup></em></p><p><em>Klebsiella pneumoniae<sup>%</sup></em></p><p><em>Klebsiella oxytoca<sup>%</sup></em></p><p><em>Morganella</em>&nbsp;<em>morganii</em></p><p><em>Proteus vulgaris</em></p><p><em>Serratia</em>&nbsp;<em>marcescens</em></p><p><strong><em>Anaerobes</em></strong></p><p><em>Bacteroides&nbsp;</em>spp<em>.</em></p><p><em>Fusobacterium&nbsp;</em>spp.</p><p><em>Peptostreptococcus&nbsp;</em>spp.</p><p><em>Clostridium perfringens</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gram-positive aerobes</em></strong></p><p><em>Enterococcus&nbsp;</em>spp.</p><p><em>Listeria monocytogenes</em></p><p><strong><em>Gram-negative aerobes</em></strong></p><p><em>Acinetobacter baumannii</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Stenotrophomonas maltophilia</em></p><p><strong><em>Anaerobes</em></strong></p><p><em>Clostridium difficile</em></p><p><strong><em>Others:</em></strong></p><p><em>Chlamydia&nbsp;</em>spp.</p><p><em>Chlamydophila</em>&nbsp;spp.</p><p><em>Mycoplasma</em>&nbsp;spp.</p><p><em>Legionella</em>&nbsp;spp.</p><p><em>Ureaplasma urealyticum</em></p></td></tr></tbody></table><p>&pound; All methicillin-resistant staphylococci are resistant to ceftriaxone.</p><p><sup>+&nbsp;</sup>Resistance rates &gt;50% in at least one region</p><p><sup>%&nbsp;</sup>ESBL producing strains are always resistant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong></p><p><em>Intravenous administration</em></p><p>After intravenous bolus administration of ceftriaxone 500 mg and 1000 mg, mean peak plasma ceftriaxone levels are approximately 120 and 200 mg/l respectively. After intravenous infusion of ceftriaxone 500 mg, 1000 mg and 2000 mg, the plasma ceftriaxone levels are approximately 80, 150 and 250 mg/l respectively.</p><p>&nbsp;</p><p><strong><em>Distribution</em></strong></p><p>The volume of distribution of ceftriaxone is 7 &ndash; 12 l. Concentrations well above the minimal inhibitory concentrations of most relevant pathogens are detectable in tissue including lung, heart, biliary tract/liver, tonsil, middle ear and nasal mucosa, bone, and in cerebrospinal, pleural, prostatic and synovial fluids. An 8 - 15% increase in mean peak plasma concentration (C<sub>max</sub>) is seen on repeated administration; steady state is reached in most cases within 48 - 72 hours depending on the route of administration.</p><p>&nbsp;</p><p><em>Penetration into particular tissues</em></p><p>Ceftriaxone penetrates the meninges. Penetration is greatest when the meninges are inflamed. Mean peak ceftriaxone concentrations in CSF in patients with bacterial meningitis are reported to be up to 25% of plasma levels compared to 2% of plasma levels in patients with uninflamed meninges. Peak ceftriaxone concentrations in CSF are reached approximately 4-6 hours after intravenous injection. Ceftriaxone crosses the placental barrier and is excreted in the breast milk at low concentrations (see section 4.6).</p><p>&nbsp;</p><p><em>Protein binding</em></p><p>Ceftriaxone is reversibly bound to albumin. Plasma protein binding is about 95 % at plasma concentrations below 100 mg/l. Binding is saturable and the bound portion decreases with rising concentration (up to 85% at a plasma concentration of 300 mg/l).</p><p>&nbsp;</p><p><strong><em>Biotransformation</em></strong></p><p>Ceftriaxone is not metabolised systemically; but is converted to inactive metabolites by the gut flora.</p><p>&nbsp;</p><p><strong><em>Elimination</em></strong></p><p>Plasma clearance of total ceftriaxone (bound and unbound) is 10 - 22 ml/min. Renal clearance is 5 - 12 ml/min. 50 - 60% of ceftriaxone is excreted unchanged in the urine, primarily by glomerular filtration, while 40 - 50% is excreted unchanged in the bile. The elimination half-life of total ceftriaxone in adults is about 8 hours.</p><p>&nbsp;</p><p><em>Patients with renal or hepatic impairment</em></p><p>In patients with renal or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only minimally altered with the half-life slightly increased (less than two fold), even in patients with severely impaired renal function.</p><p>&nbsp;</p><p>The relatively modest increase in half-life in renal impairment is explained by a compensatory increase in non-renal clearance, resulting from a decrease in protein binding and corresponding increase in non-renal clearance of total ceftriaxone.</p><p>&nbsp;</p><p>In patients with hepatic impairment, the elimination half-life of ceftriaxone is not increased, due to a compensatory increase in renal clearance. This is also due to an increase in plasma free fraction of ceftriaxone contributing to the observed paradoxical increase in total drug clearance, with an increase in volume of distribution paralleling that of total clearance.</p><p>&nbsp;</p><p><em>Older people</em></p><p>In older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The half-life of ceftriaxone is prolonged in neonates. From birth to 14 days of age, the levels of free ceftriaxone may be further increased by factors such as reduced glomerular filtration and altered protein binding. During childhood, the half-life is lower than in neonates or adults.</p><p>&nbsp;</p><p>The plasma clearance and volume of distribution of total ceftriaxone are greater in neonates, infants and children than in adults.</p><p>&nbsp;</p><p><strong><em>Linearity/non-linearity</em></strong></p><p>The pharmacokinetics of ceftriaxone are non-linear and all basic pharmacokinetic parameters, except the elimination half-life, are dose dependent if based on total drug concentrations, increasing less than proportionally with dose. Non-linearity is due to saturation of plasma protein binding and is therefore observed for total plasma ceftriaxone but not for free (unbound) ceftriaxone.</p><p>&nbsp;</p><p><strong><em>Pharmacokinetic/pharmacodynamic relationship</em></strong></p><p>As with other beta-lactams, the pharmacokinetic-pharmacodynamic index demonstrating the best correlation with&nbsp;<em>in vivo</em>&nbsp;efficacy is the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftriaxone for individual target species (i.e. %T &gt; MIC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">There is evidence from animal studies that high doses of ceftriaxone calcium salt led to formation of concrements and precipitates in the gallbladder of dogs and monkeys, which proved to be reversible. Animal studies produced no evidence of toxicity to reproduction and genotoxicity. Carcinogenicity studies on ceftriaxone were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin, fluconazole and aminoglycosides.</p><p>&nbsp;</p><p>Solutions containing Cefaxon should not be mixed with or added to other agents except those mentioned in section 6.6. In particular diluents containing calcium, (e.g. Ringer&#39;s solution, Hartmann&#39;s solution) should not be used to reconstitute Cefaxon vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Cefaxon must not be mixed or administered simultaneously with calcium containing solutions including total parenteral nutrition (see section 4.2, 4.3, 4.4 and 4.8).</p><p>&nbsp;</p><p>If treatment with a combination of another antibiotic with Cefaxon is intended, administration should not occur in the same syringe or in the same infusion solution.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials: 36 months.

Chemical and physical in-use stability of the reconstituted product and diluted solution has been demonstrated for at least 6 hours at or below 25°C or 24 hours at 2-8°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than the times stated above for the chemical and physical in-use stability.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions of the reconstituted medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colorless sealed vials with white caps.</p><p>&nbsp;</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concentrations for the intravenous injection: 100 mg/ml (Please refer to section 4.2 for further information).</p><p>&nbsp;</p><p><strong><em>Preparation of solutions for infusion</em></strong></p><p>The use of freshly prepared solutions is recommended. For storage conditions of the reconstituted medicinal product, see section 6.3.</p><p>&nbsp;</p><p>The infusion line should be flushed after each administration.</p><p>&nbsp;</p><p><strong><em>Cefaxon 1000 mg Powder for Solution for Infusion</em></strong></p><p>For IV injection 1000 mg Cefaxon is dissolved in 10 ml of water for injection. The injection should be administered over 5 minutes, directly into the vein or via the tubing of an intravenous infusion.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Dilution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Solvent</strong></p></td><td style="vertical-align:top"><p><strong>Volume (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Approximate concentration (mg/ml)</strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>One 1000 mg vial reconstituted with 10 ml of WFI</p></td><td style="vertical-align:top"><p>0.9% sodium chloride solution</p><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>40</p></td><td rowspan="5" style="vertical-align:top"><p>19.7</p></td></tr><tr><td style="vertical-align:top"><p>0.45% sodium chloride with 2.5% dextrose</p></td></tr><tr><td style="vertical-align:top"><p>5% Dextrose</p></td></tr><tr><td style="vertical-align:top"><p>10% Dextrose</p></td></tr><tr><td style="vertical-align:top"><p>Water for injection</p></td></tr></tbody></table><p>&nbsp;</p><p>The displacement volume of 1000 mg of Cefaxon is 0.72 ml in water for injection. When adding 10 ml of water for injections, the final concentration of the reconstituted solution is 93.28 mg/ml.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22 November 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>